BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Current and emerging treatments. J Am Acad Dermatol 2020;82:1061-82. [PMID: 31604100 DOI: 10.1016/j.jaad.2019.08.089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wolfe C, McCoin N. Abdominal Pain in the Immunocompromised Patient. Emerg Med Clin North Am 2021;39:807-20. [PMID: 34600639 DOI: 10.1016/j.emc.2021.07.002] [Reference Citation Analysis]
2 Willems D, Hiligsmann M, van der Zee HH, Sayed CJ, Evers SMAA. Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study. Patient 2021. [PMID: 34368925 DOI: 10.1007/s40271-021-00539-7] [Reference Citation Analysis]
3 Choi E, Ooi XT, Chandran NS. Hidradenitis suppurativa in pediatric patients. J Am Acad Dermatol 2020:S0190-9622(20)32436-1. [PMID: 32822788 DOI: 10.1016/j.jaad.2020.08.045] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Sánchez-Martínez EM, García-Ruiz R, Moneva-Léniz LM, Mateu-Puchades A. Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction. Dermatol Ther 2020;33:e14054. [PMID: 32700796 DOI: 10.1111/dth.14054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis 2021;12:20406223211055920. [PMID: 34840709 DOI: 10.1177/20406223211055920] [Reference Citation Analysis]
6 Han Y, Wang C, Klinger K, Rajpal DK, Zhu C. An integrative network-based approach for drug target indication expansion. PLoS One 2021;16:e0253614. [PMID: 34242265 DOI: 10.1371/journal.pone.0253614] [Reference Citation Analysis]
7 Rumberger BE, Boarder EL, Owens SL, Howell MD. Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis. Inflamm Res 2020;69:967-73. [DOI: 10.1007/s00011-020-01381-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Rozzo G, Ramondetta A, Fierro MT, Dapavo P, Ribero S. Moderate-to-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak. Dermatol Ther 2020;33:e13680. [PMID: 32447800 DOI: 10.1111/dth.13680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 João AL, Cunha N, Cabete J. Intermammary Hidradenitis Suppurativa: Considerations on a Unique Presentation. Skin Appendage Disord 2021;7:318-21. [PMID: 34307482 DOI: 10.1159/000514363] [Reference Citation Analysis]
10 Howes R, Ingram JR, Thomas KS, Collier F, Rodrigues JN; THESEUS Survey collaborator group. The surgical management of hidradenitis suppurativa in the United Kingdom: a national survey of care pathways informing the THESEUS study. J Plast Reconstr Aesthet Surg 2021:S1748-6815(21)00422-8. [PMID: 34674976 DOI: 10.1016/j.bjps.2021.08.038] [Reference Citation Analysis]
11 Gutierrez N, Cohen PR. Ectopic Hidradenitis Suppurativa: Case Report and Review of Literature. Cureus 2021;13:e12966. [PMID: 33659117 DOI: 10.7759/cureus.12966] [Reference Citation Analysis]
12 Shah RA, Hsu JI, Patel RR, Mui UN, Tyring SK. Antibiotic resistance in dermatology: The scope of the problem and strategies to address it. J Am Acad Dermatol 2021:S0190-9622(21)02502-0. [PMID: 34555484 DOI: 10.1016/j.jaad.2021.09.024] [Reference Citation Analysis]
13 Ramos FJM, Ruiz RG, Puchades AM. Golimumab, as an alternative treatment in patients with coexisting hidradenitis suppurativa and arthritis after adalimumab failure: Report of two cases. Dermatol Ther 2021;:e15266. [PMID: 34913547 DOI: 10.1111/dth.15266] [Reference Citation Analysis]
14 Chen SX, Lopez CG, Kassamali B, Luskin MR, Charrow A. Hidradenitis suppurativa in acute myeloid leukemia: Review of disease course and management. JAAD Case Rep 2022;19:44-7. [PMID: 34917723 DOI: 10.1016/j.jdcr.2021.11.012] [Reference Citation Analysis]